A new positioning device to limit breathing movement during lung cancer radiation
Tests a body-positioning and breath-holding device during radiation for non-small cell lung cancer.
Plain-language title generated from the registry record
Registry title: Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)
Key facts
- Where
- Tianjin, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07916129, who can take part
Where in China
- Tianjin Medical University Cancer Institute and HospitalTianjin, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tianjin Medical University Cancer Institute and Hospital
- Trial code
- NCT07916129
- Record updated
- 4 November 2026
- Original description
This single-center study evaluates a novel body position and breath-holding device for lung cancer patients receiving stereotactic body radiation therapy. We will enroll 50 patients with single peripheral non-small cell lung cancer, compare tumor movement and radiation dose distribution with and without the device, to test if the device is safe, feasible and can improve treatment accuracy.Read full original descriptionShow less
Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)
This single-center study evaluates a novel body position and breath-holding device for lung cancer patients receiving stereotactic body radiation therapy. We will enroll 50 patients with single peripheral non-small cell lung cancer, compare tumor movement and radiation dose distribution with and without the device, to test if the device is safe, feasible and can improve treatment accuracy.
Inclusion: Voluntarily participate and sign written informed consent; Age ≥18 years, gender unlimited; Clinically diagnosed with single peripheral lung cancer, assessed as suitable for SBRT; Males or females of childbearing age willing to take contraceptive measures during the trial; Female of childbearing age must have a negative pregnancy test within 7 days before treatment, and all patients use adequate contraception during treatment and for 4 weeks after.
Exclusion: Intolerant or unwilling to receive the integrated respiratory suppression and positioning immobilization device for radiotherapy localization; Patients with central or ultra-central lung cancer; Currently participating or planning to participate in other clinical trials; Refuse or be unable to sign the informed consent form for this trial; Patients planned to receive SBRT for multiple pulmonary lesions; Patients assessed by the investigators of this trial as unsuitable for SBRT treatment.